PDCD1LG2 and breast cancer: The expression of immune suppressive ICMs (PD-L1, PD-L2, and HVEM), immune stimulatory ICMs (CD137-L, Ox40-L, CD27-L, and ICOS-L), and EGFR in breast cancer cells was enhanced by RT with HT, consequently enhancing anti-tumor responses.